Stephen C. Glover - 12 Dec 2022 Form 4 Insider Report for ZyVersa Therapeutics, Inc. (ZVSA)

Role
Chief Executive Officer, Director
Signature
/s/ Peter Wolfe, attorney-in-fact for Stephen C. Glover
Issuer symbol
ZVSA
Transactions as of
12 Dec 2022
Net transactions value
$0
Form type
4
Filing time
14 Dec 2022, 18:24:50 UTC
Previous filing
29 Jun 2022
Next filing
19 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZVSA Common Stock Award +448,909 448,909 12 Dec 2022 Direct F1
transaction ZVSA Common Stock Award +85,442 85,442 12 Dec 2022 See footnote F1, F2
transaction ZVSA Common Stock Award +49,636 49,636 12 Dec 2022 See footnote F1, F3
transaction ZVSA Common Stock Award +43,847 43,847 12 Dec 2022 See footnote F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZVSA Series A Convertible Preferred Stock Award +18 +1% 1,750 12 Dec 2022 Common Stock 1,750 $10.00 Direct F5, F12
transaction ZVSA Stock Options (right to buy) Award $0 +138,980 $0.000000 138,980 12 Dec 2022 Common Stock 138,980 $5.03 Direct F6
transaction ZVSA Stock Options (right to buy) Award $0 +168,761 $0.000000 168,761 12 Dec 2022 Common Stock 168,761 $5.03 Direct F7
transaction ZVSA Stock Options (right to buy) Award $0 +264,838 $0.000000 264,838 12 Dec 2022 Common Stock 264,838 $11.58 Direct F8
transaction ZVSA Stock Options (right to buy) Award $0 +126,138 $0.000000 126,138 12 Dec 2022 Common Stock 126,138 $16.36 Direct F9
transaction ZVSA Stock Options (right to buy) Award $0 +79,417 $0.000000 79,417 12 Dec 2022 Common Stock 79,147 $16.36 Direct F10
transaction ZVSA Warrant (right to buy) Award $0 +70,881 $0.000000 70,881 12 Dec 2022 Common Stock 70,881 $6.90 Direct F11
transaction ZVSA Warrant (right to buy) Award $0 +3,022 $0.000000 3,022 12 Dec 2022 Common Stock 3,022 $11.58 Direct F11
transaction ZVSA Warrant (right to buy) Award $0 +17,903 $0.000000 17,903 12 Dec 2022 Common Stock 17,903 $11.58 See footnote F2, F11
transaction ZVSA Warrant (right to buy) Award +1,750 1,750 12 Dec 2022 Common Stock 1,750 $11.50 Direct F11, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Received in connection with the Issuer's business combination with Larkspur Health Acquisition Corp., a Delaware corporation ("Larkspur") in accordance with the terms of the Business Combination Agreement, dated July 20, 2022, as amended (the "Business Combination Agreement") by and among ZyVersa Therapeutics, Inc., a Florida corporation ("Old ZyVersa"), the Securityholder Representative (as defined in the Business Combination Agreement) named therein, Larkspur, and Larkspur Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Larkspur ("Merger Sub") pursuant to which Merger Sub merged with and into Old ZyVersa (the "Acquisition Merger"), with Old Zyversa as the surviving company of the Acquisition Merger and, after giving effecting to such Acquisition Merger, Old ZyVersa became a wholly-owned subsidiary of Larkspur and changed its name to the Issuer.
F2 The securities are held of record by Asclepius Life Sciences Fund, L.P ("ALS Fund"). Reporting Person serves as the managing member of ALS Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 The securities are held of record by Asclepius Master Fund, LTD. ("AM Fund"). Reporting Person serves as the managing director of AM Fund. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 The securities are held of record by MedicaRx Inc. ("MRx"). Reporting Person serves as the managing director of MRx. Reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F5 The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.
F6 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 11, 2015.
F7 100% of the option is immediately exercisable. The option vested on October 28, 2016.
F8 100% of the option is immediately exercisable. The option vested in 3 equal annual installments commencing on April 2, 2020.
F9 The option vests in 3 equal annual installments commencing on February 8, 2022.
F10 The option vests in 3 equal annual installments commencing on January 28, 2023.
F11 The warrant is immediately exercisable in full.
F12 The Reporting Person paid $1,000 per share of Series A Convertible Preferred Stock and warrants in an amount equal to 100% of the common shares issuable upon conversion of the Series A Convertible Preferred Stock for an aggregate of $17,500. No half shares of the Series A Convertible Preferred Stock were issued, therefore, the reporting person received 18 shares of such preferred stock instead of 17.5.